Treatment with the antibody-drug conjugate TORL-1-23 was safe and tolerable in heavily pretreated, CLDN6-positive advanced solid tumors, including platinum-resistant ovarian cancer.
Amycretin, a dual pathway, oral weight loss drug, was found to be safe and tolerable in a phase 1 study and led to weight loss of up to 13% in people with overweight and obesity.